PE-22-88 dosage and protocol
Natural antidepressant peptide derived from Spadin that blocks TREK-1 channels for mood enhancement
- Vial size: 5 mg
- Concentration: Intranasal
- Administration: nasal
Research areas
- Depression
- Mood Enhancement
- Cognitive Function
- Neuroprotection
Quick start
- Reconstitute: Prepare the 5 mg vial as a nasal solution; volume not specified in the record, so calculate dose per spray from the chosen volume
- Typical dose: 400 mcg once daily for 6 weeks
- Easy measuring: Intranasal use; no syringe unit conversion applies
- Storage: Refrigerate at 2-8°C
Dosing protocol
| Phase | Dose | Frequency | Volume |
|---|---|---|---|
| Standard | 400 | Once daily | Intranasal |
How it works
PE-22-88 is presented as a spadin-derived peptide that blocks the TREK-1 potassium channel, the same target as spadin and the better-documented analogue PE-22-28. TREK-1 blockade increases excitability of mood-related neurons and serotonergic activity, and genetic or pharmacological TREK-1 inhibition produces antidepressant-like effects in rodents. Despite the record's wording, spadin analogues are synthetic peptides, not natural products. Published research on spadin and its shortened analogues comes from rodent studies showing faster-onset antidepressant-like behaviour, increased hippocampal neurogenesis and neuroprotection in stroke models. A specific peptide designated PE-22-88 is not well described in the peer-reviewed literature, so its sequence, potency and pharmacokinetics cannot be confirmed, and it may be a variant name or mislabel for a related analogue. No human clinical trials exist. Intranasal delivery, as listed in this record's protocol, has not been characterised for this compound, and claims about mood enhancement in people are unverified.
Reconstitution steps
- Prepare for intranasal administration
Storage
Store in refrigerator at 2-8°C
Important notes
- Faster-acting than traditional antidepressants
- Blocks TREK-1 channel to improve mood and learning
- Take in morning intranasally
- High safety profile compared to pharmaceuticals
- Short-term use with cycling recommended
- Limited clinical data available
Supplies
- Intranasal spray bottle